ClearPoint Neuro reports Q4 revenue $10.4M (+34% YoY); FY 2025 revenue $37.0M (+18%); guides FY 2026 $52-56M

ClearPoint Neuro, Inc.

Q4 2025 revenue $10.4M including $1.2M from recent IRRAS acquisition; organic growth 19% YoY.
Full-year 2025 revenue $37.0M, 11th consecutive year of growth; 14% organic YoY increase.
2026 revenue guidance $52-56M, reflecting expected double-digit growth across all four product segments.
Completed IRRAS acquisition in Nov 2025, adding neurocritical care line and $20M additional financing from Oberland Capital.
Cash and equivalents $45.9M at Dec 31, 2025, up from $20.1M a year ago.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.